This material has been developed for HCPs within the context of the virtual congress of the European Rhinologic Society (ERS) in collaboration with the International Society of Inflammation and Allergy of the Nose (ISIAN) and the International Rhinologic Society (IRS), September 26-30, 2021. Novartis Pharma AG provides this information to the best of its knowledge at the time of production of this item in July 2021 and is not for further distribution, dissemination or use without the prior written authorization of Novartis Pharma AG.
The content follows the Summary of Product Characteristics (SmPC) for Xolair® (omalizumab) as approved in the EU.
Xolair® is approved in the EU for Severe Allergic Asthma, Severe CRSwNP* and Chronic Spontaneous Urticaria. This product is also approved for use in further countries. Please go to www.respiratoryandallergyersrhinology2021booth.com to see the full list countries where this product is approved and for the full EU PI (SmPC) (English language version/Greek language version).
Novartis Pharma AG provides the information of the local country approvals for Xolair® to the best of its knowledge at the time of production of this item in July 2021, however, you should always consult the local Novartis affiliate directly to confirm the current status of local approval and product availability in your country.
Prescribing information (PI) may vary depending on local approval in each country. Therefore, before prescribing any product always refer to local materials such as the PI and/or SmPC. Please go to www.respiratoryandallergyersrhinology2021booth.com for the full EU PI (SmPC) (English language version/Greek language version).
For purposes of this conference, best efforts were undertaken by Novartis to ensure compliance with the Code of the European Federation of Pharmaceutical Industries and Associations (EFPIA).
Please note, that recording, reproduction, distribution (including on social media), public communication and/or content modification are not allowed. All content is proprietary to Novartis Pharma AG and subject to copyright protection.
CRSwNP: chronic rhinosinusitis with nasal polyps
Prior to prescription, please consult the Summary of Product Characteristics available on the stand.
Πριν τη συνταγογράφηση συμβουλευθείτε την ΠΧΠ που διατίθεται στο εκθετήριο.
Package/Price: XOLAIR PS.INJ.SOL. 75MG/0,5MG BTx1 PF SYR X 0,5ML (LIQUID) H.P. 128,06€, R.P. 180,98€, XOLAIR PS.INJ.SOL. 150MG/1,0ML BTx1PF.SYR x 1,0 ML (LIQUID) H.P 263,63€, R.P 348,10€ (Price bulletin date: 29/6/2021 – in case of amendment of the PB the latest price is effective, VAT included)
Prescription status: Restricted medical prescription from specialist, due to the need for monitoring during treatment.
Novartis (Hellas) S.A.C.I., National Rd. No 1, 12th klm, GR-114 51 Metamorphosis, GREECE, Tel: +30 210 281 17 12 Pharmacovigilance, +30 210 2828812